Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
Eiki IchiharaDaijiro HaradaKoji InoueTakuo ShibayamaShinobu HosokawaDaizo KishinoShingo HaritaNobuaki OchiNaohiro OdaNaofumi HaraKatsuyuki HottaYoshinobu MaedaKatsuyuki KiuraPublished in: Cancer immunology, immunotherapy : CII (2020)
The duration of response to prior EGFR TKIs could be a predictive marker of ICI therapy in EGFR-mutant NSCLC patients.